Sectoral Asset Management Has Lifted Portola Pharmaceuticals (PTLA) Holding By $4.55 Million; Shorts at KIADIS PHARMA N V ORDINARY SHARES NETHE (KIADF) Lowered By 42.9%
February 22, 2018 - By reb123z
Sectoral Asset Management Inc increased Portola Pharmaceuticals (PTLA) stake by 19.96% reported in 2017Q3 SEC filing. Sectoral Asset Management Inc acquired 84,271 shares as Portola Pharmaceuticals (PTLA)’s stock rose 22.73%. The Sectoral Asset Management Inc holds 506,414 shares with $27.36 million value, up from 422,143 last quarter. Portola Pharmaceuticals now has $2.94 billion valuation. The stock increased 0.38% or $0.17 during the last trading session, reaching $45.08. About 529,767 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since February 22, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.
KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF) had a decrease of 42.9% in short interest. KIADF’s SI was 41,400 shares in February as released by FINRA. Its down 42.9% from 72,500 shares previously. With 100 avg volume, 414 days are for KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF)’s short sellers to cover KIADF’s short positions. The SI to KIADIS PHARMA N V ORDINARY SHARES NETHE’s float is 0.36%. It closed at $13.94221 lastly. It is down 0.00% since February 22, 2017 and is . It has underperformed by 16.70% the S&P500.
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, focuses on the research and development of cell immunotherapy products for the treatment of blood cancers and inherited blood disorders in the Netherlands. The company has market cap of $247.53 million. The firm focuses on therapeutic indications, including leukaemia, a common form of blood cancer; and thalassemia, an inherited blood disorder. It currently has negative earnings. The Company’s products comprise ATIR101 , a Phase II clinical trial product, which addresses the risk and limitations of hematopoietic stem cell transplantation in blood cancer; and ATIR201, which is in Phase I/II clinical development for inherited blood disorders with an initial focus on thalassemia.
Sectoral Asset Management Inc decreased Envision Healthcare stake by 19,620 shares to 113,600 valued at $5.11 million in 2017Q3. It also reduced Pfizer Inc (NYSE:PFE) stake by 448,297 shares and now owns 957,673 shares. Edwards Lifescience (NYSE:EW) was reduced too.
Investors sentiment increased to 2.16 in 2017 Q3. Its up 0.85, from 1.31 in 2017Q2. It increased, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Kazazian Asset Mgmt Limited Liability owns 12,241 shares. Teacher Retirement System Of Texas owns 5,310 shares. Panagora Asset Mngmt holds 0% or 8,537 shares in its portfolio. Evanson Asset Mgmt Limited Liability Corporation invested in 5,000 shares or 0.06% of the stock. Cubist Systematic Strategies Limited stated it has 4,039 shares or 0.01% of all its holdings. Laurion Capital Mgmt LP stated it has 0.11% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Atika Capital Mngmt Ltd Llc holds 0.9% or 58,000 shares in its portfolio. State Board Of Administration Of Florida Retirement System reported 24,946 shares. Moreover, Victory Inc has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). 120,362 were accumulated by Guggenheim Cap Limited Liability Company. Rosenblum Silverman Sutton S F Inc Ca accumulated 129,330 shares. The Pennsylvania-based Sei Investments has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Wellington Management Grp Llp has 0.07% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 5.46 million shares. San Francisco Sentry Investment Gp (Ca) holds 150 shares. Fortaleza Asset Mgmt Inc reported 0.29% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).
Since December 15, 2017, it had 0 insider purchases, and 1 insider sale for $563,950 activity. $563,950 worth of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) shares were sold by Wolff Henry Ward.